Most clinical-stage biotech companies generate no revenue. They spend money — sometimes enormous amounts of it — running trials and paying staff, while waiting on FDA decisions that may be years away. The question every investor in these companies needs to ask is simple: how long can they keep the lights on? That question is answered by a metric called cash runway — one of the most important but frequently overlooked figures in any biotech investor’s analysis toolkit.
The Short Answer
| Cash runway is the estimated period of time a company can continue funding its operations based on its current cash and cash equivalents, given its current rate of spending — called the burn rate. It is typically expressed in months or quarters. A company with $50 million in cash and a quarterly burn rate of $10 million has approximately five quarters — or about 15 months — of cash runway. When runway runs short, the company must raise additional capital, which often means diluting existing shareholders. |
Why Cash Runway Matters in Biotech More Than Most Sectors
In most industries, investors focus on revenue, profit margins, and cash flow from operations. Biotech is different. The majority of publicly traded biotech companies — particularly small-cap and mid-cap names — are pre-revenue. They have no product sales. Their entire financial model is built around deploying capital to generate the clinical data that will eventually (they hope) lead to an approved, commercial product.
This structure makes the balance sheet uniquely critical. A biotech company with strong pipeline data but insufficient cash to complete its pivotal trial is in a precarious position. It may be forced to raise capital at a dilutive price, partner away rights to its lead program, or — in the worst case — halt development entirely. Understanding cash runway is not a secondary consideration in biotech investing; for many small-cap names, it is the primary risk variable.
How to Calculate Cash Runway
Cash runway is calculated by dividing the company’s total cash and cash equivalents (found on the balance sheet) by its quarterly or monthly cash burn rate (found in the cash flow statement, specifically the net cash used in operating activities). Most biotech companies report their cash position and provide a runway estimate in their quarterly earnings releases and 10-Q filings.
Many companies will also state their runway directly in their financial commentary: ‘We believe our existing cash and investments are sufficient to fund our operations through the end of [year].’ This management guidance is a starting point, but investors should verify it against the reported burn rate, as guidance can be based on optimistic spending assumptions.
What Short Runway Means for a Biotech Stock
A company with less than 12 months of cash runway faces what is often called a funding cliff — a point at which it will need to raise capital to survive. Approaching a funding cliff typically introduces several headwinds for a stock: management attention is diverted toward fundraising, the company may be forced to raise capital at unfavorable terms, and the market often prices in the expected dilution before it occurs.
A company with less than 6 months of runway will often see its auditor include a ‘going concern’ note in its financial statements — a formal acknowledgment that there is substantial doubt about the company’s ability to continue as a going concern. Going concern notes are serious red flags for investors.
How Biotechs Raise Additional Capital
When runway runs short, biotech companies have several options. The most common is an equity raise — either a follow-on public offering, where new shares are sold to institutional investors, or an at-the-market (ATM) offering, where the company sells shares gradually into the open market over time. Both methods dilute existing shareholders — they increase the total share count, reducing each shareholder’s percentage ownership.
Companies can also raise capital through convertible notes (debt that converts to equity at a set price), licensing deals or partnerships (in which a larger company pays upfront for rights to a program), or non-dilutive grants from government or foundations. Non-dilutive funding is highly valued precisely because it does not reduce existing shareholders’ ownership.
Reading Runway in Earnings Season
Biotech earnings releases — even for companies with no revenue — are important reading for investors, primarily because of the cash update. Look for: current cash position, quarterly burn rate, and management’s runway guidance. Compare management’s guidance to the implied runway from the burn rate. A significant gap — especially if management is projecting longer runway than the math supports — is worth investigating further in the subsequent 10-Q filing.
What This Does Not Guarantee
| A long cash runway does not mean a company is a good investment. A company can have three years of runway and still have a drug that fails in Phase 2. Runway is a risk variable — it tells you how much time the company has to execute — but it says nothing about the quality of the pipeline or the likelihood of clinical success. Investors should use runway as one input in a broader analysis, not as a primary investment thesis. |
Key Takeaways
- Cash runway is the estimated time a company can fund operations based on current cash divided by current burn rate — typically expressed in months
- Most clinical-stage biotech companies are pre-revenue, making the balance sheet and runway among their most important financial metrics
- Companies with less than 12 months of runway face a funding cliff and may be forced to raise capital at dilutive terms
- A ‘going concern’ note from auditors — typically triggered when runway is below 12 months — is a serious warning signal
- Biotechs raise capital through follow-on equity offerings, ATM programs, convertible notes, licensing deals, and non-dilutive grants
- Dilutive raises reduce existing shareholders’ percentage ownership — the more shares issued, the greater the dilution
- Runway should be verified against the reported burn rate, not taken solely from management guidance
Sources
1. SEC EDGAR — 10-Q and 10-K filings: https://www.sec.gov/cgi-bin/browse-edgar
2. SEC — Understanding Financial Statements: https://www.sec.gov/investor/pubs/begfinstmtguide.htm
3. FDA — Drug Development Process: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process
4. BioPharma Catalyst: https://www.biopharmacatalyst.com
Disclaimer
This article is based on publicly available regulatory information, company filings, and authoritative industry sources. All information was current as of the date of publication. BioTech Stocks Daily has not received compensation from any company referenced in this article in connection with this coverage.
This article contains references to forward-looking statements and clinical projections. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those projected. Past clinical results do not guarantee future outcomes.
The information provided in this article is for informational and educational purposes only and does not constitute financial, investment, or medical advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decision.
For full terms, see our Disclaimer.